Colorectal Cancer

Next-generation sequencing shows limited survival benefit but identifies key mutations that may inform future treatment strategies.

Novel models incorporating tumor deposits outperform tumor TNM in predicting outcomes.

A study finds that $100 rideshare rides for follow-up colonoscopy after fecal immunochemical test (FIT) doubled completion rates, reduced colorectal cancer (CRC) deaths, and lowered health care costs.

A novel image-based deep learning approach achieves high accuracy and interpretability, offering potential for clinical decision support.

Combining perioperative comfort care with targeted operating room nursing reduces stress, pain, and recovery times in patients with colorectal cancer, according to one study.

A national survey finds patients want personal contact after positive cancer results, with psychosocial fears outweighing cost and transportation concerns.

A 6-year follow-up study finds berberine reduces adenoma and neoplasm rates after polypectomy, highlighting its potential for long-term chemoprevention.

A study finds 70 years may be a key cutoff for oxaliplatin benefit in stage III colorectal cancer, with no survival advantage seen in older patients or those with stage II disease.

A randomized trial finds that default mailed outreach outperforms active choice strategies for initiating colorectal cancer screening in young adults.

Data from the 2021 National Health Interview Survey showed racial/ethnic differences in colorectal cancer screening were due to demographic and socioeconomic factors, except for low colonoscopy use in Asian individuals.

In a large fecal immunochemical test-based screening program, high adenoma detection rates lowered interval colorectal cancer (CRC) incidence and mortality, but not CRC-specific survival.

A New Zealand study finds patients are open to remote and general practitioner-led care when it is tailored to their needs.

The study aims to build an accurate, interpretable model for stage III colorectal cancer prognosis.

Patients and providers find the Colon Age tool acceptable and useful for individualizing colorectal cancer risk and encouraging earlier screening.

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

Metformin use may enhance progression-free survival (PFS) in patients receiving first-line systemic therapy for patients with metastatic colorectal cancer.

Why is colorectal cancer affecting more young people, and what can be done to prevent it?

Widespread noncompliance with federal cost-sharing rules exists, particularly impacting Medicare beneficiaries and patient-preferred prep options, study finds.

Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs).

Initiating fecal immunochemical test (FIT) screening before age 50 can significantly reduce colorectal cancer incidence and mortality, according to one study.

Structured exercise programs should be a part of the standard of care for colon cancer following adjuvant chemotherapy, authors of the CHALLENGE study recommended.

A circulating tumor DNA (ctDNA) blood test demonstrated high sensitivity and specificity for colorectal cancer (CRC) detection in a large average-risk population, study finds.

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.

A novel machine learning model enhances colorectal cancer (CRC) prognosis and immunotherapy response prediction by integrating clinical data and immune gene expression.

Patients with chronic conditions are less likely to be diagnosed via screening and face higher mortality when cancer is detected in emergency settings, according to one study.